VJHemOnc is committed to improving our service to you

ASCO 2019 | Characterizing bridging strategies for CAR T-cell therapy

VJHemOnc is committed to improving our service to you

Karlo Perica

Karlo Perica, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, explains the rationale behind a retrospective review of adult patients with R/R acute lymphoblastic leukemia (ALL) treated with 19-28z CAR-T therapy seeking to characterize bridging strategies. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter